Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Qurient Clinical Trial Information
- Phone Number: (KST) +82-31-8060-1610
- Email: clinicaltrial_info@qurient.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Atlantic Health System Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced or metastatic solid tumors, that have progressed following standard of care therapy or for which there is no standard therapy which confers clinical benefit
- Measurable disease per RECIST v 1.1
- ECOG performance status 0 or 1
- Life expectancy of at least 3 months
- Age ≥ 18 years
- Signed, written IRB-approved informed consent form
Exclusion Criteria:
- New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months
- Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec (females) and >450 msec (males)
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Active, poorly controlled autoimmune or inflammatory diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose escalation (Q702)
Participants will receive escalating doses of Q702
|
The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702
Time Frame: 28 days of cycle 1
|
28 days of cycle 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in the area under curve (AUC) of Q702
Time Frame: Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
|
Change in the maximum plasma concentration (Cmax) of Q702
Time Frame: Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
|
Change in the time of maximum plasma concentration (Tmax) of Q702
Time Frame: Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22
|
|
Tumor response using RECIST version 1.1 throughout study
Time Frame: Baseline up to approximately 2 years
|
Baseline up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Q702-ONC-P1-US001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.